UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): December 14, 2007

Nabi Biopharmaceuticals

(Exact name of registrant as specified in its charter)

Delaware	**000-04829**	**59-1212264**
State or other jurisdiction of incorporation	**Commission File Number**	**IRS Employer Identification No.**

12276 Wilkins Avenue Rockville, MD 20852
(Address of principal executive offices) (Zip code)

(301) 770-3099
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure

In connection with the Company's investor conference call on December 14, 2007 sponsored by Bear Stearns, the Company intends to review the slides furnished as Exhibit 99.1.

The information in this Item 7.01 shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, and it shall not be incorporated by reference into any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing. Furthermore, the furnishing of the information included in this Item 7.01 is not intended to constitute a determination by the registrant that the information is material or that the dissemination of the information is required by Regulation FD.

Item 9.01. Financial Statements and Exhibits

Exhibit number	Description
99.1	Slides

The information included in the exhibits to this Current Report on Form 8-K is furnished pursuant to Items 7.01 and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section, and shall not be incorporated by reference into any filing under the Securities Act or the Exchange Act, regardless of any general incorporation language in such filing. Furthermore, the furnishing of the information included in these exhibits to this Report is not intended to constitute a determination by the registrant that the information is material or that the dissemination of the information is required by Regulation FD.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Nabi Biopharmaceuticals

Date: December 14, 2007

By: /s/ Jordan I. Siegel
Jordan I. Siegel
Senior Vice President, Finance and Administration
Chief Financial Officer and Treasurer

Index of Exhibits

Exhibit number	Description
99.1	Slides

Exhibit 99.1

NABI
BIOPHARMACEUTICALS

Leveraging Our Opportunity

Bear Stearns Conference Call
December 14, 2007

Forward Looking Statements

Certain matters Nabi will discuss today are forward-looking statements including statements about our use of proceeds from the sale of the Biologics SBU. You can identify these forward-looking statements because they involve our expectations, beliefs, projections, anticipations or other characterizations of future events or circumstances. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements as a result of any number of factors. These factors include, but are not limited to, risks relating to our strategic alternatives process and our ability to: successfully partner with third parties to fund, develop, and manufacture our pipeline products, including NicVAX and our gram-positive infections products; obtain successful clinical trial results; realize anticipated cost savings related to job elimination due to greater than anticipated severance-related costs or other factors; maintain a sufficient cash balance and generate sufficient cash flow from milestone or royalty payments to fund our development and commercialization activities; attract and maintain the human and financial resources to bring to market products in development; depend upon third parties to manufacture or fill our products; achieve approval and market acceptance of our products; enter into and maintain arrangements with third parties to market and sell our products; manufacture NicVAX or other products; comply with reporting and payment obligations under government rebate and pricing programs; raise additional capital on acceptable terms, or at all; and re-pay our outstanding convertible senior notes when due. Many of these factors are more fully discussed, as are other factors, in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and our Quarterly Report on Form 10-Q for the quarter ended September 29, 2007 filed with the Securities and Exchange Commission.

NABI BIOPHARMACEUTICALS

Pipeline Update

- **In Progress: Partner NicVAX**
  - Planning for pivotal phase III trials 4514 & 4515 underway
  - Ongoing immunogenicity study, phase II 4513
  - Active partnership discussions
- **In Progress: Partner StaphVAX**
  - Process development of PVL and alpha toxin vaccine components underway
  - Active partnership discussions
- **In Progress: Transfer of Manufacturing Processes**
  - NicVAX clinical material secured to end of phase III
  - Transfer from Biotest to a CMO supplier for *Go to Market*
  - StaphVAX phase I materials

NABI BIOPHARMACEUTICALS

NABI
BIOPHARMACEUTICALS

NicVAX

Primary and Secondary Abstinence Measures



NABI BIOPHARMACEUTICALS

Improve Antibody Response



NABI BIOPHARMACEUTICALS

Exceeding the Effect Threshold Drives Greater Abstinence

Schedule 2	12-Month Continuous Abstinence Rates
NicVAX 400 µg *Above Threshold at TQD*	22% (n=6/27) p=0.011
NicVAX 400 µg *Below Threshold at TQD*	11% (n=2/19) p=0.37
Placebo	6% (n=6/98)

Intent to Treat Population

NABI BIOPHARMACEUTICALS

Decide on Optimum Abstinence Measure



NABI BIOPHARMACEUTICALS

Claims Data on Secondary Benefits



NABI BIOPHARMACEUTICALS

NicVAX Critical Milestones by Quarter



NicVAX launch 4Q12

NABI BIOPHARMACEUTICALS

Corporate Priorities

- **Develop and Partner NicVAX and StaphVAX**
- **Complete the Strategic Alternatives Process**
- **Maximize Shareholder Value: Share repurchase program underway**

NABI BIOPHARMACEUTICALS

NABI
BIOPHARMACEUTICALS